Dr. Jia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
LL S600
Cleveland, OH 44106Phone+1 410-328-6110Fax+1 216-286-3989
Summary
- Dr. Angela Jia is a radiation oncologist in Cleveland, OH and is affiliated with UH Cleveland Medical Center. She received her medical degree from Weill Cornell Medicine and has been in practice 6 years. She also speaks multiple languages, including Chinese (Mandarin). She specializes in urologic cancer. She has more than 30 publications and over 500 citings.
Education & Training
Johns Hopkins UniversityResidency, Radiation Oncology, 2018 - 2022
University of MarylandInternship, Internal Medicine, 2017 - 2018
Weill Cornell MedicineClass of 2017
Columbia UniversityPhD, Pathology , 2007 - 2013
Certifications & Licensure
OH State Medical License 2021 - 2025
DC State Medical License 2021 - 2022- American Board of Radiology Radiation Oncology
Clinical Trials
- MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) Start of enrollment: 2024 May 24
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiol...Alec Zhu, James A Proudfoot, Elai Davicioni, Ashley E Ross, Valentina I Petkov
European Urology Oncology. 2024-12-01 - Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.Soumyajit Roy, Fred Saad, Yilun Sun, Shawn Malone, Daniel E Spratt
European Journal of Cancer. 2024-11-01 - 1 citationsEarly Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the ...Soumyajit Roy, Yilun Sun, Kim N Chi, Michael Ong, Shawn Malone
The Journal of Urology. 2024-11-01
Journal Articles
- Radiotherapeutic management of oligometastatic disease in low- and middle-income countries: A current state of affairs and perspectives on future implementation.Jia AY, Deek M, Phillips R, Appl Rad Oncol., 9/9/2020
Press Mentions
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate CancerOctober 16th, 2024
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
